Jul 07, 2023 / 02:00AM GMT
Operator
Thank you very much for coming despite your busy schedule. It's time. Now we would like to start the Eisai Company Limited Conference for Media and Investors on traditional approval for LEQEMBI in the U.S. Today's session is in a hybrid manner, on on-site and online. Those who are taking part in the meeting on site, you have a handout, so please confirm them and those who are taking part in online, please continue reviewing the meeting. Let me introduce the presenter and the Director Representative for Corporate Officer and CEO, Mr. Haruo Naito. CEO, Naito, the floor is yours.
Haruo Naito - Eisai Co., Ltd. - CEO, Representative Corporate Officer & Director
So now, so they can be -- we obtained the traditional approval of the LEQEMBI. I would like to explain. So on July 6, and by the FDA that I am extremely happy to announce that Eisai has received the approval since the Aricept Research is at the late 1980 and in the past 40 years, it is a great pleasure for those of us in the pharmaceutical industry, particularly those of us who have interacted with the
Eisai Co Ltd Media and Investor Conference Transcript
Feb 13, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers